TABR Capital Management LLC Makes New $1.62 Million Investment in Bristol Myers Squibb Company $BMY

TABR Capital Management LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,624,000.

Other large investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank boosted its stake in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after buying an additional 3,277 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $221,000. Finally, Nebula Research & Development LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter worth $405,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BMY shares. Citigroup upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Cantor Fitzgerald boosted their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Scotiabank restated a “sector perform” rating and set a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $61.71.

Bristol Myers Squibb Trading Up 0.5%

Bristol Myers Squibb stock opened at $59.44 on Wednesday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm’s 50-day moving average is $59.76 and its 200-day moving average is $53.92. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The company has a market cap of $121.36 billion, a P/E ratio of 17.23, a PEG ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the company earned $1.67 EPS. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.28 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.